top of page
Scientific background
  • Tang Q, Su Z, Gu W, Rustgi AK. Mutant p53 on the Path to Metastasis. Trends Cancer. 6(1), 62-73. (2020) doi: 10.1016/j.trecan.2019.11.004. Epub 2019 Dec 16. PMID: 31952783; PMCID: PMC7485681.

  • Li M, Li S, Du C, Zhang Y, Li Y, Chu L, Han X, Galons H, Zhang Y, Sun H, Yu P. Exosomes from different cells: Characteristics, modifications, and therapeutic applications. Eur J Med Chem. 11, 207-112784 (2020)

  • Walker, S. et al. Extracellular vesicle-based drug delivery systems for cancer treatment. Theranostics vol. 9(26), 8001-8017 (2019) doi:10.7150/thno.37097

  • Perets, N., Hertz, S., London, M., Offen, D. Intranasal administration of exosomes derived from mesenchymal stem cells ameliorates autistic-like behaviors of BTBR mice. Mol Autism. 9, 57 (2018) doi: 10.1186/s13229-018-0240-6.

  • Burdakov, V.S., Kovalev, R.A., Pantina, R.A. et al. Exosomes Transfer p53 between Cells and Can Suppress Growth and Proliferation of p53-Negative Cells. Cell Tiss. Biol. 12, 20–26 (2018). 

  • Parrales, A., Iwakuma, T. Targeting oncogenic mutant p53 for cancer therapy. Frontiers in Oncology. 5, 288–288 (2015)

  • Rivli, N., Brosh, R., Oren, M., Rotter, V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer. 2(4), 466-74. (2011) doi: 10.1177/1947601911408889.

  • Almazov, V.P., Kochetkov, D.V., Chumakov, P.M. The use of p53 as a tool for human cancer therapy Mol Biol (Mosk). 41, 947–963 (2007)

  • Tendler, Y., Panshin, A., Weisinger, G. & Zinder, O. Identification of cytoplasmic p53 protein in corneal epithelium of vertebrates. Exp. Eye Res. 82, 674–681 (2006).

  • Pokroy, R., Tendler, Y., Pollack, A., Zinder, O. & Weisinger, G. P53 expression in the normal murine eye. Invest Ophthalmol. Vis. Sci. 43, 1736–41 (2002).

  • Vogelstein, B. & Kinzler, K. W. P53 function and dysfunction. Cell. 70, 523–526 (1997).

  • Lane, D. P. p53: guardian of the genome. Nature. 358, 15–16 (1992).

bottom of page